Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Romark Laboratories L.c.
Romark Laboratories L.c.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Alinia
Nitazoxanide
2004-07-21
Diarrhea
,
Giardiasis
,
Cryptosporidiosis
,
Protozoan infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Nitazoxanide
hepatitis b
,
chronic hepatitis b
,
gastroenteritis
,
clostridioides difficile
,
colitis
,
crohn disease
,
hepatitis
,
hepatitis a
,
hepatitis c
,
chronic hepatitis c
,
chronic hepatitis
,
covid-19
,
human influenza
,
enterovirus
,
rhinovirus
,
enterovirus infections
,
rotavirus infections
,
diarrhea
,
clostridium infections
,
amebiasis
,
amebic dysentery
,
hiv infections
,
cryptosporidiosis
,
infections
,
communicable diseases
,
adenoviridae infections
,
caliciviridae infections
Benzocaine
covid-19
,
enterovirus
,
rhinovirus
,
enterovirus infections
Tenofovir
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Alfacalcidol
hepatitis c
,
chronic hepatitis c
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Albinterferon alfa-2b
hepatitis c
,
chronic hepatitis c
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Retinol
covid-19
,
enterovirus
,
rhinovirus
,
enterovirus infections
Fendrix
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Fluzone
human influenza
Flumist
human influenza
Flucelvax
human influenza
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use